
|Videos|March 25, 2014
Augmenting the Benefit of Hormonal Therapy in Breast Cancer
Author(s)Debu Tripathy, MD
Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses augmenting the benefit of hormonal therapy in breast cancer.
Advertisement
Clinical Pearls
Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses augmenting the benefit of hormonal therapy in breast cancer.
- The CDK4/6 inhibitor palbociclib has yielded exciting preliminarily results
- In a phase II study, the combination of palbociclib and letrozole tripled PFS compared with letrozole alone (26.1 months versus 7.5 months)
- The HDAC inhibitor entinostat plus hormonal therapy was found to improve survival in a phase II study
- Src inhibition showed benefit in a trial
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Early Relapse Guides Use of CAR T vs Other Options in LBCL
4
FDA Fast-Tracks Muzastotug Combo in MSS Metastatic Colorectal Cancer
5








































